Global Enteric Disease Testing and Therapeutic Market Size By Type (Bacterial disease, Viral disease), By Application (Hospital, Research), By Region, And Segment Forecasts, 2023 to 2032

The Global Enteric Disease Testing and Therapeutic Market was valued at USD 8.2 billion in 2023 and is projected to reach USD 14.5 billion by 2031, growing at a CAGR of 6.9% during the forecast period 2023-2031. The increasing burden of enteric diseases worldwide, rising demand for rapid diagnostic testing, and advancements in therapeutic treatments are key drivers fueling the market growth.

Enteric diseases, which primarily affect the gastrointestinal tract, are caused by bacteria, viruses, and parasites. Common conditions include cholera, salmonellosis, shigellosis, rotavirus, and norovirus infections. The market is witnessing strong demand for innovative diagnostic technologies, vaccines, and antimicrobial therapies to combat rising infection rates, particularly in developing regions with poor sanitation and limited healthcare access.

Market Drivers

Rising Incidence of Enteric Diseases

The growing prevalence of waterborne and foodborne infections, especially in developing nations, is a major driver. Poor sanitation, contaminated drinking water, and inadequate hygiene practices significantly contribute to disease outbreaks.

Advancements in Diagnostic Technologies

Innovative molecular diagnostic tests, point-of-care (POC) testing kits, and rapid antigen detection methods have improved the accuracy and speed of diagnosing enteric diseases. The shift towards automated and multiplex PCR-based testing platforms is enhancing efficiency.

Increasing Adoption of Vaccination Programs

Global health organizations and governments are investing in preventive vaccination strategies against major enteric infections such as cholera and rotavirus, thereby driving market demand for vaccines.

Market Restraints

High Cost of Advanced Diagnostic Tests

Despite advancements, molecular and automated diagnostic tests remain expensive, limiting their adoption in low-income countries with inadequate healthcare budgets.

Antimicrobial Resistance (AMR) Concerns

The overuse of antibiotics and antimicrobial agents in treating enteric diseases has led to a rise in drug-resistant bacterial strains, posing a major challenge for treatment effectiveness.

Market Opportunities

Expansion of Diagnostic Testing in Developing Regions

The increasing investments in healthcare infrastructure in emerging economies, along with the expansion of diagnostic laboratories and mobile healthcare units, present lucrative market opportunities.

Development of Novel Therapeutics

Companies are focusing on next-generation probiotics, microbiome-based therapies, and non-antibiotic treatment approaches to combat enteric infections with minimal resistance issues.

Integration of AI in Diagnostics

The use of AI-powered predictive analytics and machine learning algorithms in diagnostic platforms is improving early detection rates and personalized treatment approaches.

Market by System Type Insights

Based on system type, the Molecular Diagnostics segment accounted for the largest market share in 2023. The growing preference for PCR-based assays, next-generation sequencing (NGS), and automated diagnostic solutions is driving this segment's growth. The Rapid Diagnostic Testing (RDT) kits segment is expected to witness the highest CAGR, owing to its cost-effectiveness and ease of use in field testing.

Market by End-Use Insights

Based on end-use, the Hospitals and Diagnostic Laboratories segment held the dominant market share in 2023, driven by the high patient influx for enteric disease testing and treatment. The Point-of-Care (POC) testing segment is anticipated to experience significant growth, fueled by rising demand for decentralized and home-based testing solutions.

Market by Regional Insights

North America held the largest share in 2023, attributed to the presence of advanced healthcare infrastructure, increased adoption of molecular diagnostics, and strong government support for infectious disease control.

Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rapid urbanization, increasing investments in healthcare facilities, and a high burden of enteric infections in countries like India, China, and Indonesia.

Europe remains a key market, supported by high awareness, strong regulatory frameworks, and government funding for enteric disease research.

Competitive Scenario

Key players operating in the Global Enteric Disease Testing and Therapeutic Market include:

bioMérieux

Abbott Laboratories

Roche Diagnostics

Danaher Corporation (Cepheid)

BD (Becton, Dickinson and Company)

Thermo Fisher Scientific

Siemens Healthineers

Eiken Chemical Co., Ltd.

Hologic, Inc.

Merck & Co.

These companies are focusing on strategic mergers & acquisitions, collaborations with research institutes, and the development of innovative testing kits and therapeutics to maintain their market position.

Scope of Work – Global Enteric Disease Testing and Therapeutic Market

Report Metric Details

Market Size (2023) USD 8.2 billion

Projected Market Size (2031) USD 14.5 billion

CAGR (2023-2031) 6.9%

Key Market Segments Molecular Diagnostics, Rapid Diagnostic Testing Kits, Traditional Culture-Based Testing

Leading Segment by System Type Molecular Diagnostics

Leading Segment by End-Use Hospitals & Diagnostic Laboratories

Key Regions North America, Europe, Asia-Pacific, Latin America, MEA

Key Players Abbott, Roche, Thermo Fisher Scientific, bioMérieux, BD, Danaher, Siemens Healthineers

Growth Drivers Rising prevalence of enteric infections, advancements in diagnostics, and vaccination programs

Market Restraints High diagnostic costs, antimicrobial resistance

Market Opportunities AI-driven diagnostics, microbiome-based therapeutics, expansion in emerging markets

Key Market Developments

December 2023: Roche launched a next-generation multiplex PCR diagnostic kit for enteric pathogens, improving rapid detection and treatment decisions.

October 2023: Abbott Laboratories introduced a new portable rapid antigen testing device targeting cholera and norovirus outbreaks in resource-limited areas.

July 2023: bioMérieux partnered with the WHO to enhance global surveillance of enteric diseases using advanced molecular diagnostic tools.

May 2023: Danaher Corporation acquired a leading microbiome-based therapeutics company to expand its treatment portfolio for enteric diseases.

FAQs

1. What is the current market size of the Global Enteric Disease Testing and Therapeutic Market?

The market was valued at USD 8.2 billion in 2023 and is expected to grow significantly by 2031.

2. What is the major growth driver of the Global Enteric Disease Testing and Therapeutic Market?

The major driver is the increasing prevalence of enteric diseases and the demand for rapid and accurate diagnostic solutions.

3. Which is the largest region during the forecast period in the Global Enteric Disease Testing and Therapeutic Market?

North America currently holds the largest market share, while Asia-Pacific is projected to be the fastest-growing region.

4. Which segment accounted for the largest market share in the Global Enteric Disease Testing and Therapeutic Market?

The Molecular Diagnostics segment dominated in 2023 due to technological advancements and high accuracy in enteric disease detection.

5. Who are the key market players in the Global Enteric Disease Testing and Therapeutic Market?

Key players include Abbott, Roche, Thermo Fisher Scientific, bioMérieux, BD, Danaher Corporation, and Siemens Healthineers.

This comprehensive report offers insights into the growth trends, opportunities, competitive landscape, and key developments in the Global Enteric Disease Testing and Therapeutic Market, ensuring data-driven decision-making for stakeholders.